Literature DB >> 10852127

Antibodies in human infectious disease.

P W Parren1, P Poignard, H J Ditzel, R A Williamson, D R Burton.   

Abstract

Investigation of human antibody responses to viral pathogens at the molecular level is revealing novel aspects of the interplay of viruses with the humoral immune system. In viral infection, at least two types of human antibody responses exist: a response to mature envelope on virions that is neutralizing and a response to immature forms of envelope (viral debris) that is not. Many pathogens have, to varying degrees, evolved envelopes to minimize antibody responses against epitopes exposed on the virion. In this article, we review recent studies on human immunodeficiency virus type 1, Ebola virus, and respiratory syncytial virus. Prion diseases are diseases of protein conformation. We have generated a large panel of antibodies recognizing the cellular prion protein (PrP(c)), some of which also react with the abnormally folded infectious prion protein (PrP(Sc)). These antibodies are being used to gain insight into both the molecular events leading to the formation of infectious PrP and the physiologic role played by PrP in normal and prion-infected cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852127     DOI: 10.1385/IR:21:2-3:265

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  58 in total

1.  Antibody binding defines a structure for an epitope that participates in the PrPC-->PrPSc conformational change.

Authors:  Z F Kanyo; K M Pan; R A Williamson; D R Burton; S B Prusiner; R J Fletterick; F E Cohen
Journal:  J Mol Biol       Date:  1999-11-05       Impact factor: 5.469

2.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

3.  Global AIDS surveillance. Part II.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1998-12-04

4.  Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD.

Authors:  J Collinge; K C Sidle; J Meads; J Ironside; A F Hill
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

5.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231).

Authors:  R Riek; S Hornemann; G Wider; R Glockshuber; K Wüthrich
Journal:  FEBS Lett       Date:  1997-08-18       Impact factor: 4.124

7.  Transmission dynamics and epidemiology of BSE in British cattle.

Authors:  R M Anderson; C A Donnelly; N M Ferguson; M E Woolhouse; C J Watt; H J Udy; S MaWhinney; S P Dunstan; T R Southwood; J W Wilesmith; J B Ryan; L J Hoinville; J E Hillerton; A R Austin; G A Wells
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

8.  Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.

Authors:  L Foresman; F Jia; Z Li; C Wang; E B Stephens; M Sahni; O Narayan; S V Joag
Journal:  AIDS Res Hum Retroviruses       Date:  1998-08-10       Impact factor: 2.205

9.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

10.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more
  5 in total

1.  Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Mónica Fonseca Aten; Brett Raynor; Estrella Peromingo; Perla Soni; Kurt D Olsen; Peter A Kiener; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies.

Authors:  Rene Alvarez; Kevin S Harrod; Wun-Ju Shieh; Sherif Zaki; Ralph A Tripp
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.

Authors:  Qing He; Alaina Mitchell; Tulin Morcol; Steve J D Bell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

4.  Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.

Authors:  Karin Stiasny; Stefan Kiermayr; Heidemarie Holzmann; Franz X Heinz
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Classification epitopes in groups based on their protein family.

Authors:  Edgar Kozlova; Benjamin Viart; Ricardo de Avila; Liza Felicori; Carlos Chavez-Olortegui
Journal:  BMC Bioinformatics       Date:  2015-12-16       Impact factor: 3.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.